Altogether, members of the specialty collected nearly 5,800 of these payments in 2024, from sources such as pharmaceutical companies and imaging device manufacturers.
Medmo and Covera Health, both based in New York, officially announced their merger on April 21, with the latter’s lead investor, Insight Partners, funding the deal.
Speaking at a Politico health care policy forum, CMS Administrator Mehmet Oz, MD, said he supports Medicaid, adding that “when you love something, you protect it.”
The insurance giant has been piloting a program to speed up reimbursement to hospitals in 10 states, reducing delays by roughly 50%. Now, the company said it will work to lift prior authorization barriers on patient care delivery. The intent is to roll out these changes nationwide by the end of 2026, UnitedHealthcare confirmed.
By and large, U.S. hospitals and health systems do not have an AI adoption problem. But many—if not most—have an execution problem: They struggle to turn a set of installed AI tools into a measurable operational value.
Family physicians and other primary care providers don’t mind being held to account for care quality by healthcare administrators. The rub is that multiple other stakeholders often demand similar levels of answerability, pulling the doctors in different directions at once.
Developed by a board-certified diagnostic and interventional radiologist, the platform was trained using subspecialty data that general AI applications typically lack.
In the three or so years since it burst into healthcare, ambient AI scribe technology has run away with the win in the market-uptake race. What has been the return on investment in all those software packages?
The U.S. Department of Justice said it worries its lawsuit could ultimately bankrupt the telehealth group, leaving little money for alleged victims. The company is said to have refused to cancel member accounts, forcing patients to file credit card disputes to get refunds. This is in addition to other arguably more serious accusations levied by the DOJ.
The idea was floated as part of a proposed budget for the state released by Democrats in the Senate. If passed, only the top 2% of corporations in California would be impacted. The levy would generate $5 billion to $8 billion annually for Medicaid.
Altogether, members of the specialty collected nearly 5,800 of these payments in 2024, from sources such as pharmaceutical companies and imaging device manufacturers.
